PRESS RELEASE published on 08/28/2023 at 13:30, 2 years 6 months ago NLS Pharmaceutics CEO Issues Letter to Shareholders
PRESS RELEASE published on 05/02/2023 at 14:45, 2 years 10 months ago NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
PRESS RELEASE published on 03/27/2023 at 14:30, 2 years 11 months ago NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
PRESS RELEASE published on 01/23/2023 at 14:30, 3 years 2 months ago NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
PRESS RELEASE published on 01/12/2023 at 14:30, 3 years 2 months ago NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Published on 03/26/2026 at 23:00, 1 hour 26 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 2 hours 21 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 2 hours 26 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 2 hours 26 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 3 hours 26 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 3 hours 38 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 5 hours 6 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 5 hours 17 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 6 hours 9 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 16 hours 56 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
